New Therapy for Metastatic Gastric and Gastroesophageal Cancers


Josep Tabernero, MD, PhD, ESMO president, director, Vall d’Hebron Institute of Oncology, Barcelona, Spain, summarizes the overall survival results from the TAGS study of trifluridine/tipiracil vs placebo in patients with metastatic gastric cancer refractory to standard therapies.


Stay in the know.
OncNet Newsletter